title: Mineralocorticoid receptor blockade in chronic kidney disease.
abstract: Mineralocorticoid receptor blockers (MRBs) have proven highly successful in the treatment of congestive heart failure and resistant hypertension. In contrast, their use in chronic kidney disease (CKD) has lagged due to the concern of hyperkalemia and, possibly, because of the incorrect assumption that traditional therapy with angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers consistently reduce aldosterone activity in all patients. Low-dose MRB therapy may offer additional antihypertensive and unique anti-inflammatory benefits in select CKD populations.
authors.affiliation: Division of Nephrology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA.
authors.forename: Andrew S
authors.initials: AS
authors.lastname: Bomback
authors.forename: Philip J
authors.initials: PJ
authors.lastname: Klemmer
mesh_terms: D000450:Aldosterone / Q000627:therapeutic use*; D000818:Animals; D048909:Diabetes Complications / Q000188:drug therapy; D006801:Humans; D006929:Hyperaldosteronism / Q000139:chemically induced; D007668:Kidney / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D007676:Kidney Failure, Chronic / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D000451:Mineralocorticoid Receptor Antagonists; D018161:Receptors, Mineralocorticoid / Q000378:metabolism
chemical_list: D000451:Mineralocorticoid Receptor Antagonists; D018161:Receptors, Mineralocorticoid; D000450:Aldosterone